## PRIVATE COMPANY LIMITED BY SHARES DIRECTORS' STATEMENT OF COMPLIANCE

## DRUG TEST LIMITED

("Company")

On

3 March 2016

Statement of compliance in relation to reduction of capital supported by solvency statement (pursuant to section 644(5) of the Companies Act 2006)

The Company has taken steps to effect the following capital reduction ("Capital Reduction") supported by a solvency statement made by the directors of the Company on 3 March 2016 pursuant to section 642 of the Companies Act 2006 ("Solvency Statement")

It is proposed that the Company's share capital be reduced from £73,100 divided into 73,100 ordinary shares of £1 00 each to £1 00 divided into 1 ordinary share of £1 00 by cancelling and extinguishing for no consideration 73,099 ordinary shares in the Company

We, being all of the directors of the Company, confirm that

- 1 the Solvency Statement was made not more than 15 days before the date on which the special resolution approving the Capital Reduction was passed, and
- a copy of the Solvency Statement was provided to every eligible member in accordance with section 642(2) of the Companies Act 2006

Signed on 3 March 2016 by each of the directors of the Company

Director & Company Secretary

GAVIN L Director

